Cargando…
Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment
Autores principales: | Chen, Lei, Wu, Eric Q. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397974/ https://www.ncbi.nlm.nih.gov/pubmed/26521120 http://dx.doi.org/10.18553/jmcp.2015.21.11.1088 |
Ejemplares similares
-
Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment
por: Trivedi, Digisha, et al.
Publicado: (2014) -
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Kim, Yundeok, et al.
Publicado: (2021) -
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022) -
Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014) -
Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians
por: Kekäle, Meri, et al.
Publicado: (2014)